Recently, the American Vaping Manufacturers Association (AVM) sent a letter to the chairman and vice-chairman of the Senate Ethics Committee, alleging that Durbin had pressured the FDA to ban all electronic cigarette products, despite being aware that the agency was legally authorized to review the tobacco applications submitted for each product prior to market approval (PMTA).
AVM cited Senator Durbin's requests in letters, Senate speeches, press releases, and private meetings to ban and restrict e-cigarette products, claiming that it believes the Senator's attempts to "interfere and influence the actions of the executing administrators" go against the Senate's ethical standards for the review process of branch agencies.
In June of this year, the FDA issued an Emergency Marketing Order (MDO) to manufacturer Juul Labs after Senator Durbin repeatedly pressured FDA Commissioner Robert Califf to take action against the company. The agency's initial denial of reasons for the order quickly became invalid, and the embarrassed regulatory agency quickly made a concession and issued a suspension order.
Senator Durbin's arrogant bullying has now become a serious threat to public health, says Amanda Wheeler, President of AVM, in a press release. "At a time where trust in public health authorities is already wavering, Durbin's shameful campaign to hijack federal policy on this critical health issue must come to an immediate end.
This letter to the Senate committee marks the second time this year that AVM has requested an investigation into corrupt practices in the FDA's pre-market review process. In July, the trade organization called on the Office of Inspector General at the Department of Health and Human Services (HHS) to investigate whether "unwarranted political pressure" from Senator Durbin and anti-vaping groups had affected the FDA's scientific procedures.
The Ethics Committee is investigating allegations of improper behavior by senators in Congress, though it rarely takes action to censure or punish lawmakers. The government watchdog group Issue One has described the committee as "an embodiment of a black hole, lacking a strong public record of the ethical culture in its meeting chambers to ensure its oversight.
It is highly unlikely that the committee will take action against DeBenn, as the majority whip of the Democratic-led institution ranks second among Democrats. Even if Republicans take over the Senate next year, the Ethics Committee is unlikely to conduct a serious investigation into DeBenn or cite his improper behavior.
Statement:
This article is compiled from third-party information and is only intended for industry exchange and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The translation of this article only serves for industry communication and research purposes.
Due to limitations in translation ability, the translated article may not fully convey the original text. Please refer to the original article for accuracy.
2FIRSTS fully aligns with the Chinese government's positions and statements on any domestic, Hong Kong, Macau, Taiwan, or foreign matters.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
